JNP - Juniper Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.10
+0.20 (+2.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.90
Open8.95
Bid4.70 x 900
Ask9.65 x 800
Day's Range8.95 - 9.25
52 Week Range4.30 - 13.25
Volume47,034
Avg. Volume84,765
Market Cap101.019M
Beta0.90
PE Ratio (TTM)182.00
EPS (TTM)0.05
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventslast month

    Edited Transcript of JNP earnings conference call or presentation 10-May-18 12:30pm GMT

    Q1 2018 Juniper Pharmaceuticals Inc Earnings Call

  • Juniper Pharmaceuticals Inc (NASDAQ:JNP): Can It Deliver A Superior ROE To The Industry?
    Simply Wall St.last month

    Juniper Pharmaceuticals Inc (NASDAQ:JNP): Can It Deliver A Superior ROE To The Industry?

    Juniper Pharmaceuticals Inc (NASDAQ:JNP) generated a below-average return on equity of 0.30% in the past 12 months, while its industry returned 12.26%. Though JNP’s recent performance is underwhelming, it isRead More...

  • Associated Presslast month

    Juniper Pharmaceuticals: 1Q Earnings Snapshot

    The Boston-based company said it had profit of 6 cents per share. The pharmaceutical company posted revenue of $15.5 million in the period. Juniper Pharmaceuticals shares have risen 67 percent since the ...

  • Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results
    PR Newswirelast month

    Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results

    Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services (JPS) Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EDT Today BOSTON ...

  • Juniper Pharmaceuticals Inc (NASDAQ:JNP): Time For A Financial Health Check
    Simply Wall St.2 months ago

    Juniper Pharmaceuticals Inc (NASDAQ:JNP): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like Juniper Pharmaceuticals Inc (NASDAQ:JNP), with a market cap of US$91.03M. However, an important fact which most ignore is: how financiallyRead More...

  • Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018
    PR Newswire2 months ago

    Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018

    Conference Call Scheduled for 8:30 a.m. EST BOSTON , May 1, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq:JNP) ("Juniper" or the "Company"), will hold a conference call on May ...

  • Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
    PR Newswire2 months ago

    Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience

    BOSTON, April 25, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business Juniper Pharma Services (JPS), today announced an exclusive worldwide license agreement with Daré Bioscience for the development and commercialization of the Company's intravaginal ring (IVR) technology platform, including its three preclinical IVR candidates targeting unmet needs in women's health. Under the agreement, Daré will be responsible for conducting all research, development, and commercial activities for this program.

  • Where Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) Earnings Growth Stands Against Its Industry
    Simply Wall St.3 months ago

    Where Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) Earnings Growth Stands Against Its Industry

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) track record on a high level, toRead More...

  • Juniper Pharmaceuticals Appoints Richard Messina to Board of Directors
    PR Newswire3 months ago

    Juniper Pharmaceuticals Appoints Richard Messina to Board of Directors

    BOSTON, March 21, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business JPS, today announced the appointment of Richard Messina to the Company's Board of Directors. As a long-term shareholder, Richard's perspective will be a valuable contribution to our ongoing process of reviewing strategic alternatives while we continue to drive growth in our core businesses," said Alicia Secor, Juniper's President and CEO.

  • At $12, Is Juniper Pharmaceuticals Inc (NASDAQ:JNP) A Buy?
    Simply Wall St.3 months ago

    At $12, Is Juniper Pharmaceuticals Inc (NASDAQ:JNP) A Buy?

    Juniper Pharmaceuticals Inc (NASDAQ:JNP), a pharmaceuticals company based in United States, led the NasdaqGS gainers with a relatively large price hike in the past couple of weeks. As a smallRead More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of JNP earnings conference call or presentation 8-Mar-18 1:30pm GMT

    Q4 2017 Juniper Pharmaceuticals Inc Earnings Call

  • Associated Press4 months ago

    Juniper Pharmaceuticals posts 4Q profit

    On a per-share basis, the Boston-based company said it had net income of 11 cents. The pharmaceutical company posted revenue of $11.8 million in the period. For the year, the company reported a loss of ...

  • Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results
    PR Newswire4 months ago

    Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results

    Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call ...

  • ACCESSWIRE4 months ago

    Juniper Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Juniper Pharmaceuticals, Inc. (NASDAQ: JNP ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 8:30 AM Eastern ...

  • Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018
    PR Newswire4 months ago

    Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018

    Conference Call Scheduled for 8:30 a.m. EST BOSTON , March 2, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on ...

  • Juniper Pharmaceuticals to Explore Strategic Alternatives
    PR Newswire5 months ago

    Juniper Pharmaceuticals to Explore Strategic Alternatives

    BOSTON, Jan. 31, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. ("Juniper" or the "Company") (JNP), a diversified healthcare company focused on women's health, today announced that it is exploring strategic alternatives in order to enhance shareholder value. The Company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives. "Over the past year, we have made important investments into our core businesses, Juniper Pharma Services and Crinone®, that supported strong double-digit revenue growth and established a strong financial foundation for Juniper," said Alicia Secor, Juniper's President and CEO.

  • Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany
    PR Newswire5 months ago

    Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany

    BOSTON, Jan. 8, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today announced the extension of its supply agreement for CRINONE® (progesterone gel) with an affiliate of Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany has marketing rights worldwide except the United States, where CRINONE® is marketed by Allergan plc. "Our longstanding collaboration with Merck KGaA, Darmstadt, Germany to supply CRINONE® progesterone gel for sale outside of the U.S. remains an extremely important core business for us.

  • Juniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress
    PR Newswire6 months ago

    Juniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress

    BOSTON, Jan. 2, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today provided financial guidance for 2018, reflecting continued strength in the Company's core businesses, Juniper Pharma Services (JPS) and CRINONE® (progesterone gel), and provided an overview of strategic priorities for 2018. The Company also announced positive top-line pharmacokinetic data from in vivo animal studies evaluating each of the Company's three IVR formulations.

  • Juniper Pharma Services' co-founder awarded CBE in the Queen's New Year's Honours List
    PR Newswire6 months ago

    Juniper Pharma Services' co-founder awarded CBE in the Queen's New Year's Honours List

    BOSTON, Dec. 29, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (JNP), a diversified healthcare company focused on women's health, today announced that Juniper Pharma Services co-founder Martyn Davies, PhD, has been appointed as a Commander of the Order of the British Empire (CBE) in Her Majesty's 2018 New Year's Honours List. Dr. Davies will officially receive his CBE medal at an Investiture in 2018. Dr. Davies has been granted one of the United Kingdom's most prestigious awards in recognition of his contribution to science and his ground-breaking achievements in pharmaceutical research and drug development.

  • Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?
    Simply Wall St.6 months ago

    Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?

    In September 2017, Juniper Pharmaceuticals Inc (NASDAQ:JNP) announced its most recent earnings update, which confirmed that the business turned profitable again after incurring losses in the last financial year. Below,Read More...

  • Capital Cube7 months ago

    ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juniper Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to JNP-US. Comparing the performance and risk of Juniper Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube7 months ago

    ETFs with exposure to Juniper Pharmaceuticals, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juniper Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to JNP-US. Comparing the performance and risk of Juniper Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is Juniper Pharmaceuticals Inc’s (JNP) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.7 months ago

    Is Juniper Pharmaceuticals Inc’s (JNP) PE Ratio A Signal To Buy For Investors?

    Juniper Pharmaceuticals Inc (NASDAQ:JNP) trades with a trailing P/E of 7.6x, which is lower than the industry average of 23.5x. While this makes JNP appear like a great stock toRead More...